Health
Finerenone limits AFib in patients with chronic kidney disease, Type 2 diabetes – Cardiovascular Business
Treatment with finerenone can help limit new-onset atrial fibrillation (AFib) among patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D), according to new data presented at ACC.21, the American College of Cardiologys 70th annual scientific session.
In the FIDELIO-DKD trial, researchers had already concluded that finerenone, a mineralocorticoid receptor antagonist, reduces the risk of cardiovascular complications in patients with CKD and T2D. This secondary analysis of that same data…
-
Business22 hours agoThese 4 ASX mining stocks are rocketing as the rare earths boom intensifies
-
General19 hours agoBunbury man Stanley J Clemons sentenced for shooting neighbour’s dog
-
Noosa News10 hours agoWarm weather could make way for rain with ‘damaging winds, large hail’
-
General21 hours agoHotel owner mocks Wollongong Council’s palm tree art after renovation refusal